Several recent studies have shown that targeting BRD4 inhibits CRC progression and chemoresistance.[49] Our study complements the current understanding of its role in the efficacy of CRC radiotherapy and guides novel strategies for its application in the treatment of CRC. The gene discussed is BRD4; the disease is colorectal carcinoma.